Valerie Bonnelle
Scientific Assistant to the Director at the Beckley Foundation
Data updated
Research Footprint
Valerie Bonnelle appears in 7 tracked papers (2022–2025), most studied alongside LSD, Psilocybin and DMT, across Microdosing, Healthy Volunteers and Chronic Pain.
Most-cited paper: Improvement in OCD symptoms associated with serotoninergic psychedelics: a retrospective online survey (28 citations).
Frequent co-authors: Amanda Feilding, Kim Kuypers and Johannes Ramaekers.
Background & Research
Dr Valerie Bonnelle is a neuroscientist with a PhD and early research background in cognitive neuroimaging at Imperial College, UCL, and Oxford University. She joined the Beckley Foundation in 2017 and has coordinated a broad portfolio of psychedelic research, including studies on LSD microdosing, chronic pain, DMT, and autonomic nervous system correlates of psychedelic experiences. More recently, she has also focused on interoception, embodied cognition, and heart-brain communication.
Key Impact
She is a researcher coordinating psychedelic studies on microdosing, pain, autonomic physiology, and peak experiences, contributing to the clinical and mechanistic understanding of psychedelic effects.
Collaboration Network
16 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Valerie Bonnelle is associated with.
Beckley Med Foundation
Non-ProfitFundación Beckley Med is a Barcelona-based psychedelic research and education organisation, partnered with the UK's Beckley Foundation, that funds and disseminates psychedelic-assisted therapy studies and provides professional training through institutional affiliations with MAPS, Grof Legacy, and CIIS. It collaborated with CITA Clinic to deliver experimental ketamine treatment to patients with treatment-resistant depression in Spain.
View stakeholder →Imperial College London
academicThe Centre for Psychedelic Research, led by Professor David Nutt and Dr. David Erritzoe, focuses heavily on the action of psychedelic drugs in the brain and their clinical utility as aides to psychotherapy. Thanks to their extensive neuroimaging studies, this group has proposed vital mechanisms for how psychedelics work, including the Entropic Brain Theory and REBUS (RElaxed Beliefs Under Psychedelics).
View stakeholder →University College London
academicThe Understanding Neuroplasticity Induced by Tryptamines (UNITY) Project was launched at University College London. UNITY represents the first-in-human study of psychedelics at UCL. The team utilizes techniques such as fMRI, eye-tracking and experience sampling to enhance our understanding of the neurobiological mechanisms predicting cognitive and mental health outcomes following psychedelic use, initially investigating the effects of DMT.
View stakeholder →